The Pharmaceutical Journal retains sole editorial responsibility.
There are many modifiable lifestyle factors that contribute to sight loss and pharmacists should be able to advise patients on how to reduce their risk.
There are more than 200 eye conditions, ranging from common problems (e.g. dry eye disease [DED], cataracts and glaucoma) to rarer diseases (e.g. ocular melanoma and vernal keratoconjunctivitis). Some of these have no symptoms and can cause loss of sight before patients even realise what is happening. There are 1.8 million people in the UK who are living with significant sight loss, 50% of which is avoidable. As such, the government’s Public Health Outcomes Framework has highlighted preventable sight loss as a health priority.
There are many services that pharmacists and healthcare professionals can signpost patients to that support the aim of reducing the incidence of preventable sight loss. This article describes how to identify patients in at-risk groups and counsel them on lifestyle changes and the treatments that are available. It also outlines the ‘red flag’ symptoms as well as when and where to refer patients.
In addition to increasing the risk of heart disease, liver disease and certain cancers, persistent alcohol misuse can also affect long-term eye health. Alcohol use has been shown to exacerbate the signs and symptoms of DED (also known as keratoconjunctivitis sicca), a condition where the eyes do not make enough tears or the tears evaporate too quickly, leading to the eyes drying out and becoming red, swollen and irritated (see Box 1). A case–control study in ten patients following ethanol ingestion demonstrated that ethanol was detected in the person’s tears and was associated with a decreased tear break-up time (through ethanol acting as a solvent), increasing tear osmolarity and disturbing cytokine production.
Box 1: Dry eye disease
The common chronic condition dry eye disease (DED) is estimated to affect between 1 in 3 and 1 in 20 people.
Symptoms, which usually affect both eyes, include:
Patients who present with the following symptoms should be referred to their GP or an eye care specialist:
For more information on identifying DED and treatment recommendations in the community pharmacy setting, see Wolffsohn et al.’s ‘Identification of dry eye conditions in community pharmacy’ and Evans & Madden’s ‘Recommending dry eye treatments in community pharmacy’.
Heavy alcohol consumption has also been associated with known causes of blindness, including age-related macular degeneration (AMD; when the cells in the central part of the retina become damaged and central vision is impacted as a result). A meta-analysis of five published studies found that heavy alcohol consumption, defined as an intake of ≥30g of alcohol/day, was associated with an increased risk of early AMD. Alcohol is thought to increase oxidative stress by modifying the mechanisms that protect against it, resulting in AMD. The link with cataracts (clouding of the lens in the eye) is less clear, but an increased prevalence of cataracts has been reported in patients with heavy alcohol consumption.
Pharmacists should counsel patients in accordance with current NHS guidance: people should not drink more than 14 units of alcohol (a unit of alcohol is defined as 10mL of pure alcohol, roughly equivalent to 8g) per week and alcohol consumption should be evenly spread over three or more days, with several alcohol-free days each week. Patients can be signposted to organisations that can help provide support alongside the NHS, including Alcohol Concern, Alcoholics Anonymous and Drinkaware.
A history of cigarette smoking has been associated with an increased risk of AMD and is related to both its incidence and progression. Current smokers have been shown to be at an increased risk of developing AMD, compared with ex-smokers and non-smokers who are exposed to second-hand smoke. Cigarette smoke has also been shown to have a dose-related relationship with the formation of cataracts. It has also been linked to diabetic retinopathy (the blockage of blood vessels at the back of the eye), DED and glaucoma (a condition affecting the optic nerve).
A cross-sectional survey of 260 teenagers found that fear of blindness was just as compelling a motivation for smoking cessation as fear of lung cancer, heart disease and stroke. Discussions relating to eye care could, therefore, help motivate patients to quit smoking.
Pharmacists and healthcare professionals should enquire on the smoking status of all patients at least once per year and should discuss it during routine consultations. They can even provide advice to patients outside of smoking cessation services or the provision of nicotine replacement therapy, including during the purchase of over-the-counter (OTC) medicines, through medicines use reviews or during local or national campaigns (e.g. No Smoking Day).
High levels of exposure to ultraviolet (UV) A and B light are known risk factors for numerous eye conditions, including cataracts and cancer. Most brands of prescription glasses now contain a UV filter, but not all sunglasses provide adequate protection. Patients should be counselled to ensure their sunglasses are either CE or BS marked (i.e. proof of conformity with European or British standards, respectively), and are the appropriate filter category for their use (filter categories range from 0 to 4, where 4 is the darkest lens). For further advice, see Box 2.
Box 2: Advice pharmacists can give patients on buying sunglasses
Source: The British Standards Institution. Sunglasses - not just about looking cool in the heat. 2002. Available at: https://www.bsigroup.com/en-GB/about-bsi/media-centre/press-releases/2002/6/Sunglasses—not-just-about-looking-cool-in-the-heat/ (accessed November 2018)
Increasing reliance on digital devices has led to a rapid increase in computer-related eye symptoms, known as computer vision syndrome (CVS). Symptoms of CVS can be divided into four categories:
For patients experiencing CVS, a range of pharmacy medicines are available over the counter, along with environmental management options, such as:
OTC treatments for eye conditions are available in a range of formulations, including sprays, drops, gels and ointments. Patients should be advised of the various products, their potential modes of action and administration methods, to allow them to make an informed decision. For further advice, see Barai and Hammond’s ‘Computer vision syndrome: causes, symptoms and management in the pharmacy’.
Pharmacists can reinforce the importance of regular sight tests; for the majority of adults, the recommended interval is every two years. However, some higher risk patient groups are recommended to have more frequent sight tests (see Box 3). Some patient groups also have additional risk factors for glaucoma (e.g. Afro–Caribbean or Asian patients, or patients who are aged 40 years and over with a family history, are living with diabetes or high blood pressure, or are taking systemic or topical corticosteroids). These patients should be signposted to their local optician if they have not had a recent sight test or have any vision concerns.
Similarly to exemptions from NHS prescription charges, some patient groups are exempt from paying for sight tests. It is worth checking with patients to see if they qualify.
Box 3: Recommended sight test frequency
Source: College of Optometrists. Knowledge skills and performance domain/The routine eye examination. 2017
Owing to the nature of introducing a foreign item onto the surface of the eye, and the warm and moist environment in the eye, improper use of contact lenses can lead to problems. Pharmacists should be aware of The Association of Optometrists’s advice for contact lens wearers in order to counsel patients effectively:
All patients taking hydroxychloroquine and chloroquine should receive regular eye screening owing to the risk of hydroxychloroquine retinopathy, as stipulated by the Royal College of Ophthalmologists. At least 7.5% of patients taking hydroxychloroquine for more than five years will have some retinal damage. Hydroxychloroquine screening schemes are still being developed across the UK; however, it is still important to remind patients about the importance of regular eye screening. The rule of five is a helpful reminder: if patients are taking more than 5mg/kg/day for more than five years, then annual eye screening is required.
Around 50% of patients with glaucoma are non-compliant with treatment. Given the consequences of treatment failure, pharmacists should consider reasons for this and assist patients to overcome any barriers they may have; this will help prevent poor clinical outcomes and potentially unnecessary polypharmacy. The case study in Box 4 demonstrates how to do this.
Box 4: Eye drop compliance and technique case study
Mrs G comes to collect her repeat medication (metformin and ramipril) from the pharmacy. You note she also has latanoprost eye drops on her repeat medications, but has not requested these for some time. You decide to ask her about her eye drops, she states she no longer needs them as she does not have any symptoms and her glaucoma has “got better”.
How to approach the situation
Glaucomatous damage is irreversible so it is important to highlight that glaucoma is a broadly symptomless disease. Intraocular pressure needs to be controlled in the long term, and kept below 24mmHg to prevent visual problems as a result of damage to the optic nerve.
As Mrs G also has diabetes and hypertension, she is at higher risk of glaucoma; therefore, it is important that all three conditions are adequately controlled. Following your discussion, it becomes apparent that Mrs G did not understand the importance of continuing to use the eye drops until her ophthalmologist agrees her intraocular pressure is acceptable or she is no longer at risk of developing visual loss within her lifetime.
What else to assess
It is important to check eye drop technique. Consider the wrist–knuckle technique developed by the Moorfields eye hospital #knowyourdrops campaign team:
OTC treatment of common eye problems in the pharmacy is often limited to management of red, sticky, gritty and sore eyes. However, pharmacists should have a good awareness of how to treat DED and bacterial conjunctivitis,, and recognise red flag symptoms (e.g. visual loss; pain; flashing lights, floaters or halos; headaches; and co-existing diabetes or hypertension).
Where established, minor eye condition schemes (MECS) involve local accredited opticians or optometrists who offer urgent appointments (see Table 1 for an overview). Patients can self-refer or be referred by a pharmacist, GP or NHS 111. Those participating in the MECS can refer patients to eye casualty or hospital eye services if required. Pharmacists are advised to check the details of MECS in their area for a definite list of referral criteria.
Table 1: Which service patients with eye problems should attend
|GP||Minor eye condition service||Eye casualty|
|Swollen eye and fever (urgent)||Painful eye*||Penetrating eye injury/eye trauma|
|Visual changes linked to headache (e.g. migraine)||Foreign body in eye||Sudden or dramatic vision changes|
|Flashing lights*||Eye pain interfering with activities of daily living|
|Floating dots*||Eye pain with eye bulging|
|Ingrowing eyelashes||Eye surgery within the past 30 days in the same eye|
|Painful red eye with reduced vision/light sensitivity|
|Painful red eye with vision loss and nausea/vomiting|
|History of uveitis/iritis plus suspicion of a new episode|
|Vision loss with headaches and scalp/jaw soreness|
|Painful eye with droopy eyelid/double vision/abnormal pupil|
|Contact lens wear with red eye/severe pain/reduced vision|
|Flashers or floaters with veils/curtains/clouds, or reduced central vision|
*Recent issue within the past six weeks
Source: Oxfordshire Local Optical Committee. Patient information leaflet for minor eye conditions scheme
Supported by RB
RB provided financial support in the production of this content.
The authors were paid by The Pharmaceutical Journal to write this article and full editorial control was maintained by the journal at all times.
Citation: The Pharmaceutical Journal DOI: 10.1211/PJ.2018.20205702
Pharmaceutical Press is the publishing division of the Royal Pharmaceutical Society, and is a leading provider of authoritative pharmaceutical information used throughout the world.Visit rpharms.com